Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation, Laser Beam Thermal Ablation, Other Ablation), By Treatment (Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation), By Application (Kidney Cancer, Liver Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Other Cancer) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global tumor ablation market size was valued at USD 1,210 million in 2021. It is anticipated to generate USD 3,889 million by 2030, growing at a CAGR of 13.85% during the forecast period (2022–2030). Factors such as modernization in ablation rechniques and devices, significantly drives the tumor ablation market demand by 2030.

Ablation is a needle-based procedure for removing malignant or unhealthy tissue. Tumor ablation is a minimally invasive surgical procedure for the treatment of solid tumors. Unique probes are used to "burn" or "freeze" tumors without surgery. The needle probe is guided and placed into cancer using computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI).

Compared to open surgery, this type of therapy requires less anesthesia, causes minor trauma and discomfort, and patients stay in the hospital for shorter periods and recover faster. The dead tumor tissue diminishes and is replaced by scar tissue over time after tumor ablation, and it may eventually disappear. Ablation can decrease tumors, which can prolong life, relieve discomfort, and even cure cancer in rare situations.

Market Dynamics

Global Tumor Ablation Market Drivers

Accelerating Prevalence of Cancer

Ablation is a procedure that kills a tumor in the liver without removing it. When a patient has a few small tumors and surgery is not an option, this approach can be helpful. Furthermore, patients receiving such treatment are less likely to require hospitalization, resulting in a higher likelihood of ablation system adoption among individuals. An increasing prevalence of breast cancer, colon cancer, prostate cancer, and lung cancer is expected to increase demand for ablation technologies to treat kidney, soft tissue, liver, and bone tumors.

As the leading cause of death, cancer is considered a universal health problem. According to the National Cancer Institute, approximately 1,806,590 new cancer cases were diagnosed in the United States in 2020. Furthermore, the American Cancer Society added that 1.8 million new malignancies were diagnosed in the United States in 2020. Additionally, the increasing worldwide prevalence of cancer is expected to increase the demand for tumor ablation devices. According to the World Health Organization, about 3.7 million new cancer cases are reported in Europe each year. As a result, the rising global prevalence of cancer is expected to provide considerable growth prospects for market players over the forecast period.

Modernization in Ablation Techniques and Devices

Ablation device improvements have improved accuracy, mobility, and cost-effectiveness, prompting market participants to launch and upgrade new devices on a regular basis. Some of the significant technological breakthroughs in the industry are irreversible electroporation, HIFU, cryoablation, and image-guided equipment. Larger and more complex cancers in various organs can now be treated thanks to advancements in existing technology and the advent of innovative ablation procedures. In addition, advances in intraprocedural imaging aim to improve treatment quality and reduce complications. Intraprocedural imaging advancements have improved treatment preparation and provided a precise assessment of the ablation zone during treatment.

To maintain a solid position in the industry, various market participants are developing and marketing innovative ablation devices. The FDA has given regulatory approval to several ablation systems. For example, Ethicon, a Johnson & Johnson subsidiary, earned FDA breakthrough device designation for microwave technology in August 2020. In addition, Sonacare Medical got FDA approval for its HIFU prostate tissue ablation device in January 2017. Such initiatives by various market players are expected to generate widespread product demand, resulting in market expansion.

Expanding Geriatric Population

The financial load on the healthcare system is growing as the aging population grows. According to the Population Reference Bureau, the number of individuals aged 65 and up in the United States will nearly quadruple by 2060, from 52 million in 2018. As the population of the elderly grows, so will the demand for ablation devices for tumor therapy, boosting the market. Furthermore, disorders like cancer and diabetes are pervasive among the elderly, who are more prone to experience complications following chemotherapy or surgical treatment.

In addition, tumor ablation market growth is likely to be aided by a combination of decreased immune system activity in the senior population and higher co-morbidities. Elderly patients with liver cancer have a poorer liver function and more co-morbidities, and they frequently seek minimally invasive operations for a speedier recovery, which drives the tumor ablation market. As the body's primary systems deteriorate with age, the geriatric population is the primary target demographic for noninvasive ablation techniques. As a result, the expanding senior population is expected to drive demand for tumor ablation systems during the projected period.

Escalating Claims for Minimally Invasive Surgeries

Several malignant and benign tumors can be treated with minimally invasive procedures to minimize the discomfort, pain, and recovery time associated with traditional surgery. Such procedures may only involve a local anesthetic and may be a viable alternative for many people who are not surgical candidates. Many of these procedures are performed on an outpatient basis, with patients typically returning home the same day, increasing the demand for ablation procedures.

Furthermore, as compared to open surgery approaches, minimally invasive surgeries offer several advantages, which are expected to drive the tumor ablation market forward. Faster healing, smaller incisions, less scarring and pain, better precision, and shorter hospital stays are advantages of minimally invasive surgery. Since ultrasound, radiofrequency ablation, and laser ablation are minimally invasive procedures, the tumor ablation market is likely to grow over the forecast period due to increased demand for minimally invasive surgery.

Global Tumor Ablation Market Restraints

Complications with Tumor Ablation Remedy

Ablation therapy of tumors has recently emerged as a potential treatment option for various cancers that affect solid organs. Complications can become more common as the number of procedures performed grows. Bleeding and damage to the target organ are the two problems of ablation that occur most frequently. On the other hand, these difficulties are arranged according to their risks. The complications that can arise from these surgical procedures can slow the expansion of the market.

Inflexible Policies and Approvals

According to the FDA, ablation devices are classified as medical devices in Class II and III. These classes necessitate more supervision and control. Class II devices require premarket notification, and class III devices require regulatory approval (PMA). Labeling requirements, manufacturing plant-established registration, medical device listing, quality systems control, and medical device reporting are the basic permissions necessary (MDR).

The FDA's Center for Devices and Radiological Health (CDRH) oversees the framework and standards for imported devices sold in the United States, including production, labeling, packaging, and storage. Companies must comply with many regulatory standards and keep appropriate documentation to gain approval and clearance. Medical gadgets cannot be sold unless specific requirements are met. If there are any flaws or complaints, the product is taken off the market.

Global Tumor Ablation Market Opportunity

Increasing people's awareness of ablation techniques

The global tumor ablation industry is anticipated to grow and benefit from increased consumer awareness of the advantages of ablation techniques over traditional treatments and surgical methods. Additionally, the growth of emerging markets and the debut of more new products create a wealth of good chances to drive the tumor ablation market forward throughout the projected period.

Regional Analysis

Based on region, the global tumor ablation market share is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle-East Africa.

North America Holds the Dominance Over Others

North America is anticipated to hold the largest market share of USD 1,063 million by 2030 at a CAGR of 13.3% during the forecast period. Government support for excellent healthcare, high disposable income, reimbursement availability, and the increasing prevalence of cancer in the United States and Canada are all factors contributing to its expansion. United States owns a significant portion of the tumor ablation market, with a market value of USD 299 million in 2021. Furthermore, the rising senior population and rising obesity rates have increased cancer risk, which is expected to drive the adoption of cancer therapy and diagnosis.

Europe is the second-largest contributor to the tumor ablation industry and is anticipated to hold a market share of USD 1,038 million by 2030 at a CAGR of 13%. Public funding in Europe's healthcare system has boosted the market. The growing geriatric population and government cancer support have expanded the market. Germany and UK have more market revenue compared to France. The market revenue of Germany and the UK were valued at USD 68 million and USD 65 million, respectively, in 2021.

The market for tumor ablation in the Asia-Pacific is expected to witness exponential growth. The Asia-Pacific market is predicted to increase due to better healthcare infrastructure and government initiatives. Economic improvements in India and China are likely to boost the market growth. Thus, collaborative partnerships and bilateral agreements with companies in this region create growth opportunities. Japan and China are growing their market gradually, with market revenue of USD 78 million and USD 67 million, respectively, in 2021.

Latin America and the Middle East and Africa have the lowest market. Increased geriatric population, cancer prevalence, minimally invasive diagnostics, and public-private partnerships will boost the tumor ablation business. In the Middle East and Africa, Saudi Arabia is the major contributor, while in Latin America, Brazil is the primary market shareholder.

Segmental Analysis

The global tumor ablation market share is categorized based on technology, treatment, and application.

Based on the technology used, radiofrequency ablation and cryoablation are the major shareholders in the global tumor ablation market.

The market revenue of radiofrequency ablation and cryoablation was valued at USD 357 million and USD 255 million, respectively, in 2021. The decreased need for opioids or other analgesics, quick recovery, and long-lasting and better pain relief than steroid injections drive the market for radiofrequency ablation. Cryoablation creates a ball of ice at a negative temperature using liquid nitrogen. Nitrogen is pumped by a probe placed into tumor tissue which destroys liver, kidney, lung, prostate, and bone tumor cells. Cryoablation patients are recovered faster with minor side effects, smaller and less scaring, less postoperative discomfort, shorter hospital stays, and less need for pain killers. This will help segment growth. The global market for radiofrequency ablation is projected to generate USD 1,089 million in 2030, growing at a CAGR of 13.2%.

Over the forecast period, microwave ablation technology is expected to see profitable growth. Unlike a radiofrequency ablation device's electric current, a microwave (MW) ablation device's energy propagates an electromagnetic field. The use of microwave ablation technology in tissue with poor electrical conductivity, such as bones and lungs, is thus improved. Larger tumor ablation volumes, consistently high temperatures, less pain during ablation, and effective heating of the cystic mass are some of this technology's significant advantages. These advantages would help this segment flourish. Additionally, the segment is anticipated to be driven by minimal procedure time (5–10 minutes), greater efficacy with few problems, and shorter hospital stays. 

Based on the treatment done, the tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation. Percutaneous ablation is the highest market shareholder and is projected to generate USD 1,453 million at a CAGR of 14.25% by 2030. Percutaneous ablation is a tumor removal procedure in which the radiofrequency probe is placed through a small incision. This method destroys target tumor cells. This segment is driven by factors like shorter surgeries, faster recoveries, and higher patient comfort.

In 2022, the surgical ablation segment will account for a sizeable portion of the market. The reasons expected to drive the market growth include rising breast and liver cancer rates and the lack of sophisticated tumor ablation treatments for these specific organs. Over the projection period, the percutaneous ablation segment is anticipated to increase profitably. Faster healing, minor scarring, and better safety are all benefits of these procedures. It is also projected that features such as a short recovery period after surgery, patient comfort, and cost-effectiveness would further increase segment demand. However, it is anticipated that the system's increased complexities may restrain its expansion, particularly in institutions with a shortage of qualified personnel.

Laparoscopic ablation is effective in delivering long-term results while yet being minimally invasive. During the projected period, this is anticipated to promote the growth of the laparoscopic ablation segment.

Application-wise, prostate cancer is the largest market holder. The global market for prostate cancer is projected to generate USD 892 million at a CAGR of 14.15% by 2030. Prostate cancer elimination uses focal therapy. MRI-guided laser ablation destroys tiny cancers and protects normal tissue. This procedure has a low risk of post-surgery incontinence and impotence, quick recovery, no need for local anesthetic, and few side effects, further driving the market. Lung cancer is anticipated to be the second-largest market holder. This category is growing because of the rising incidence of lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC).

The market is heavily dominated by liver cancer. The increasing prevalence of primary liver and bile duct cancer explains this. The market is divided into categories for kidney, liver, breast, lung, prostate, and other types of cancer. Other cancers are covered in this section, including ENT cancer and bone metastases. It is projected that the availability of cutting-edge techniques and rising cancer prevalence will promote market expansion.

The market for kidney cancer is expected to expand profitably over the forecast period. Treatment for kidney tumors using radiofrequency and microwave ablation technology is effective. Patients with solitary kidneys, tumors smaller than 4 cm, and a delayed pace of postoperative recovery are candidates for kidney tumor ablation. According to projections made by the American Cancer Society, seventy-nine thousand additional instances of kidney cancer will be identified in 2022. Additionally, with the increased use of medical imaging, more instances are anticipated to be diagnosed, raising the need for treatment procedures throughout the forecast period.

The lung tumor ablation market is anticipated to expand during the projected period. This can be related to the disease's rising prevalence. For instance, non-small cell lung cancer (NSCLC), which accounted for 85% of all lung cancer cases, accounted for roughly 11.6% of the world's new cancer cases in 2018. Because radiofrequency ablation is frequently used to treat NSCL, market growth is projected.

Impact of covid-19

COVID-19 is a contagious respiratory disease that has affected millions of people worldwide. The pandemic has prompted the healthcare industry to undertake significant actions, with companies, countries, and organizations racing to develop therapeutic & preventive interventions. Countries, governments, and businesses have been implementing strategies and responding accordingly to address the situation at hand. In many countries, the impact of COVID-19 was amplified through other occurrences, such as the African swine fever or wildfires.

The CRT products sector, like many industries, has been severely impacted. COVID-19 has had a substantial influence on the market, including supply chain problems, a drop in sales, a reduction in prices due to the cancellation of elective surgeries, and operational challenges. For example, Abbott, a worldwide provider in the cardiac rhythm management device market, reported a reduction in cardiovascular sales growth in 2020.

Market Recovery Timeline

Past the initial panic and uncertainty caused by COVID-19, corporations and organizations immediately took constructive measures to aid the recovery of the market and enterprises. Among many of the methods employed were policy and financial stimulation, constraint flexibility, conditional exclusions, and other development initiatives. For example, Abbott launched four diagnostic tests for COVID-19 in 2020. The high returns from these sales offset the loss in revenue in different business segments.

The American College of Cardiology (ACC), the Canadian Association of Interventional Cardiology (CAIC), and other North American cardiology societies provided directives for reinstating intrusive cardiovascular operations in an efficient and responsible manner after the apex of COVID-19 has elapsed. These rules aided the economic recovery of CRT devices. 

The COVID-19 pandemic accelerated the adoption of telehealth to monitor and manage patients with arrhythmias. This trend is expected to continue to post the pandemic. Remote monitoring has emerged as a tool for lowering the risk of exposure to the virus, especially in the case of cardiac patients. Overall, the pandemic has significantly impacted the cardiac rhythm management devices industry and created opportunities for those willing to leverage them.

Recent Developments

• In December 2022, Medtronic finished enrolling participants in a crucial trial assessing a novel pulsed field ablation device for atrial fibrillation patients.
• In October 2022, First Patient Enrolled in APEX-AV Study Evaluating AlphaVac F1885 PE System for Pulmonary Embolism Treatment, according to AngioDynamics.
• In December 2022, Premier Inc. and Mermaid Medical Group announced new cooperation.
• In December 2022, Acotec Scientific Holdings Limited's majority stake will be purchased by Boston Scientific through a strategic investment.